M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: Cetuximab

First Posted Date: 2006-10-26

Last Posted Date: 2012-09-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT00392769

Locations: 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States
🇺🇸
New York Presbyterian Hospital-Cornell Medical Center, New York, New York, United States

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Phase 2

Completed

Conditions: BCR-ABL1 Fusion Protein Expression
Recurrent Acute Lymphoblastic Leukemia
t(9;22)
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Philadelphia Chromosome Positive
Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dasatinib
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Methotrexate
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2006-10-20

Last Posted Date: 2024-02-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 107

Registration Number: NCT00390793

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Radiation Therapy
Behavioral: Questionnaire
Drug: Bicalutamide
Drug: Leuprolide
Drug: Goserelin
Drug: Flutamide

First Posted Date: 2006-10-17

Last Posted Date: 2012-08-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00388804

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2006-10-16

Last Posted Date: 2014-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00388154

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
The Woman's Hospital of Texas, Houston, Texas, United States
🇺🇸
St. Lukes Episcopal Hospital, Houston, Texas, United States

Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma

Not Applicable

Completed

Conditions: Non-Hodgkin's Lymphoma
Lymphoma

Interventions: Drug: Rituximab
Drug: Zevalin

First Posted Date: 2006-10-12

Last Posted Date: 2013-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT00387023

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma

Phase 1

Active, not recruiting

Conditions: Melanoma
Eye Disease

Interventions: Procedure: Sentinel Lymph Node Mapping and Biopsy

First Posted Date: 2006-10-12

Last Posted Date: 2024-10-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 38

Registration Number: NCT00386906

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients

Not Applicable

Completed

Conditions: Leukemia

Interventions: Drug: Imatinib Mesylate

First Posted Date: 2006-10-11

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00386373

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Psychosocial Impact of Cancer-Related Female Infertility

Completed

Conditions: Hodgkin's Disease
Cervical Cancer
Breast Cancer
Lymphoma

Interventions: Behavioral: Telephone Survey

First Posted Date: 2006-10-11

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 239

Registration Number: NCT00386217

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease

Phase 2

Completed

Conditions: Hodgkin's Disease

Interventions: Drug: Gemcitabine
Drug: Fludarabine
Drug: Melphalan
Drug: Antithymocyte Globulin
Procedure: Allogeneic Stem Cell Infusion
Drug: Tacrolimus
Drug: Filgrastim (G-CSF)
Drug: Methotrexate

First Posted Date: 2006-10-11

Last Posted Date: 2018-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT00385788

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Spousal Relationships and Pain in Metastatic Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Questionnaire
Behavioral: Interview

First Posted Date: 2006-10-11

Last Posted Date: 2015-07-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 548

Registration Number: NCT00386620

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy